

Critics denounce first genome map as premature

San Francisco

from "islands of linkage" within the past

diagnostic tests, but the market for tests for the relatively rare single-gene disorders is too small to provide the required return on the investment.

Stock analysts have thus criticized Collaborative on the grounds that its